Insights into the mechanisms governing P01 scorpion toxin effect against U87 glioblastoma cells oncogenesis

Front Pharmacol. 2023 Jun 23:14:1203247. doi: 10.3389/fphar.2023.1203247. eCollection 2023.

Abstract

The emerging concept of small conductance Ca2+-activated potassium channels (SKCa) as pharmacological target for cancer treatment has significantly increased in recent years. In this study, we isolated the P01 toxin from Androctonus australis (Aa) scorpion venom and investigated its effect on biological properties of glioblastoma U87, breast MDA-MB231 and colon adenocarcinoma LS174 cancer cell lines. Our results showed that P01 was active only on U87 glioblastoma cells. It inhibited their proliferation, adhesion and migration with IC50 values in the micromolar range. We have also shown that P01 reduced the amplitude of the currents recorded in HEK293 cells expressing SK2 channels with an IC50 value of 3 pM, while it had no effect on those expressing SK3 channels. The investigation of the SKCa channels expression pattern showed that SK2 transcripts were expressed differently in the three cancer cell lines. Particularly, we highlighted the presence of SK2 isoforms in U87 cells, which could explain and rely on the specific activity of P01 on this cell line. These experimental data highlighted the usefulness of scorpion peptides to decipher the role of SKCa channels in the tumorigenesis process, and develop potential therapeutic molecules targeting glioblastoma with high selectivity.

Keywords: P01 toxin; SK2 channel subtype; androctonus australis scorpion venom; glioblastoma; small conductance calcium activated potassium channel.

Grants and funding

This study was supported partly by the Tunisian Ministry of Higher Education and Scientific Research (LR 20 IPT 01), and by grants from the University of Tours, the “Région Centre-Val de Loire” “INSERM,” the MOTIVHEALTH network, Canceropôle Grand Ouest, la Ligue Contre le Cancer de l’inter région Bretagne, Centre, Pays de la Loire, the Institut National du Cancer (INCa-PLBIO18-151), with financial support from Inserm Cancer and des “ministères de l’Europe et des affaires étrangères; et de l’enseignement supérieur, de la recherche et de l’innovation.”